Skip to main content
. 2018 Oct 20;14(13):1883–1891. doi: 10.7150/ijbs.27854

Figure 3.

Figure 3

Shikonin inhibited PKM2 activity and re-sensitized T24 resistant BC cells to cisplatin. (A) PKM2 activity in T24 resistant cells treated with 0.4 μM shikonin (SKN). (B) The expression of PKM2 in T24 resistant cells treated with 0.4 μM shikonin and 25 µM cisplatin (Cis) alone or their combination (C+S). Left, the representative western blots; right, the densitometry analysis of western blot (n=3). (C, D, and E) T24 resistant cells were treated with 0.4 μM shikonin and 25 µM cisplatin alone or their combination for 24 h. C, the cell viability was analyzed by MTT assay. D, the apoptosis was analyzed by Hoechst 33258 staining. E, the ATP level was analyzed. (F) The expression of PKM2 in T24 resistant cell transfected with PKM2 siRNA. (G) The T24 resistant cells were transfected with PKM2 siRNA, and subsequently treated with cisplatin as indicated for 24 h. The cell viability was analyzed by MTT assay. N, p>0.05; *, p<0.05; **, p<0.01.